title: MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
abstract: The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
authors.affiliation: Institut National de la Sante et de la Recherche Médicale, U711, Paris, France.
authors.forename: Sibille
authors.initials: S
authors.lastname: Everhard
authors.forename: Gentian
authors.initials: G
authors.lastname: Kaloshi
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Crinière
authors.forename: Alexandra
authors.initials: A
authors.lastname: Benouaich-Amiel
authors.forename: Julie
authors.initials: J
authors.lastname: Lejeune
authors.forename: Yannick
authors.initials: Y
authors.lastname: Marie
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
authors.forename: Michèle
authors.initials: M
authors.lastname: Kujas
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Khê
authors.initials: K
authors.lastname: Hoang-Xuan
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Joëlle
authors.initials: J
authors.lastname: Thillet
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases; D004252:DNA Mutational Analysis; D045643:DNA Repair Enzymes; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005819:Genetic Markers / Q000187:drug effects / Q000235:genetics; D005910:Glioma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000187:drug effects* / Q000235:genetics; D015996:Survival Rate; D000077204:Temozolomide; D025803:Tumor Suppressor Protein p14ARF / Q000235:genetics*; D025521:Tumor Suppressor Proteins
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D005819:Genetic Markers; D025803:Tumor Suppressor Protein p14ARF; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide